GammaCan to Present its Anti-Melanoma Technology at the 2007 ILSI BioMed Conference

  
    
  
  
    
      GammaCan International, Inc. ("GammaCan" or "the Company") (OTCBB:GCAN), 
      a developer of immunotherapies for the treatment of cancer, today 
      announced that Patrick Schnegelsberg, Chief Executive Officer, is 
      scheduled to present VitiGam™, GammaCan's lead 
      product under development for the treatment of Stage III and Stage IV 
      melanoma, at the 2007 ILSI BioMed 2007 Conference.
    
    
      The Conference will be held from June 5th 
      through June 7th at the David Intercontinental 
      Hotel, in Tel Aviv, Israel. GammaCan’s 
      presentation is scheduled during the Cancer Session, which will take 
      place on Wednesday, June 6th, 2007.
    
    
      About GammaCan
    
    
      GammaCan develops innovative immunotherapy and related approaches to 
      treat cancer. GammaCan's platform technology is based on the use of 
      IgGs, a safe, relatively non-toxic human plasma-derived product used to 
      treat a variety of immune deficiencies and autoimmune diseases. In 
      cancer, IgG-based therapies work by strengthening the patient's immune 
      system. Many experts currently view immunotherapy as a future 
      alternative to chemotherapy. For more information about GammaCan, visit www.GammaCan.com.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company expects to commence human 
      clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide both, specific 
      anti-melanoma activity (directed against melanoma cells), and 
      non-specific anti-cancer activity.
    
    
      About Melanoma
    
    
      Melanoma is a deadly form of skin cancer. According to the American 
      Cancer Society, melanoma accounts for approximately 4% of all skin 
      cancers but causes about 75% of all skin cancer-related deaths. An 
      estimated 62,000 people will be diagnosed with and nearly 8,000 people 
      will die from melanoma in the U.S. alone in 2007. If rapidly diagnosed 
      and surgically removed, early-stage melanoma is usually curable. 
      However, for patients with metastatic melanoma (including Stage II and 
      Stage IV), the prognosis is poor resulting from limited treatment 
      alternatives, a median survival time of 8.5 months, and a 5-year 
      survival rate of 3%. There has been little change in these results for 
      in excess of 25 years. The incidence of melanoma has increased more 
      rapidly than any other cancer during the past 10 years. The last drug to 
      treat patients with metastatic melanoma was approved by the FDA over 30 
      years ago.
    
    
      Safe Harbor Statement:
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding: the commercialization of anti-cancer 
      immunotherapies and the Company's efforts to develop therapies to boost 
      the immune systems of cancer patients by the use of IgG-based therapy. 
      Actual outcomes and the Company's actual results could differ materially 
      from those in such forward-looking statements. Factors that could cause 
      actual results to differ materially include risks and uncertainties such 
      as the inability to finance the planned development of the technology, 
      the inability to hire appropriate staff to develop the technology, 
      unforeseen technical difficulties in developing the technology, the 
      inability to obtain regulatory approval for human use, competitors' 
      therapies proving to be more effective, cheaper or otherwise preferable 
      for consumers, the inability to market a product, all of which could, 
      among other things, delay or prevent product release, as well as other 
      factors expressed from time to time in GammaCan's periodic filings with 
      the Securities and Exchange Commission (the "SEC"). As a result, this 
      press release should be read in conjunction with GammaCan's periodic 
      filings with the SEC, which are incorporated herein by reference. The 
      forward-looking statements contained herein are made only as of the date 
      of this press release, and GammaCan undertakes no obligation to publicly 
      update such forward-looking statements to reflect subsequent events or 
      circumstances.